These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

93 related articles for article (PubMed ID: 20826841)

  • 1. Nuclear phospho-Akt increase predicts synergy of PI3K inhibition and doxorubicin in breast and ovarian cancer.
    Wallin JJ; Guan J; Prior WW; Edgar KA; Kassees R; Sampath D; Belvin M; Friedman LS
    Sci Transl Med; 2010 Sep; 2(48):48ra66. PubMed ID: 20826841
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Differential enhancement of the anti-cancer effect of doxorubicin by Akt inhibitors on human breast cancer cells with differing genetic backgrounds.
    Wang YA; Johnson SK; Brown BL; Dobson PR
    Oncol Rep; 2009 Feb; 21(2):437-42. PubMed ID: 19148520
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Predictive biomarkers of sensitivity to the phosphatidylinositol 3' kinase inhibitor GDC-0941 in breast cancer preclinical models.
    O'Brien C; Wallin JJ; Sampath D; GuhaThakurta D; Savage H; Punnoose EA; Guan J; Berry L; Prior WW; Amler LC; Belvin M; Friedman LS; Lackner MR
    Clin Cancer Res; 2010 Jul; 16(14):3670-83. PubMed ID: 20453058
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Inhibition of the phosphatidylinositol 3-kinase/Akt pathway by inositol pentakisphosphate results in antiangiogenic and antitumor effects.
    Maffucci T; Piccolo E; Cumashi A; Iezzi M; Riley AM; Saiardi A; Godage HY; Rossi C; Broggini M; Iacobelli S; Potter BV; Innocenti P; Falasca M
    Cancer Res; 2005 Sep; 65(18):8339-49. PubMed ID: 16166311
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Differential responses to doxorubicin-induced phosphorylation and activation of Akt in human breast cancer cells.
    Li X; Lu Y; Liang K; Liu B; Fan Z
    Breast Cancer Res; 2005; 7(5):R589-97. PubMed ID: 16168102
    [TBL] [Abstract][Full Text] [Related]  

  • 6. GDC-0941, a novel class I selective PI3K inhibitor, enhances the efficacy of docetaxel in human breast cancer models by increasing cell death in vitro and in vivo.
    Wallin JJ; Guan J; Prior WW; Lee LB; Berry L; Belmont LD; Koeppen H; Belvin M; Friedman LS; Sampath D
    Clin Cancer Res; 2012 Jul; 18(14):3901-11. PubMed ID: 22586300
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Elesclomol, counteracted by Akt survival signaling, enhances the apoptotic effect of chemotherapy drugs in breast cancer cells.
    Qu Y; Wang J; Sim MS; Liu B; Giuliano A; Barsoum J; Cui X
    Breast Cancer Res Treat; 2010 Jun; 121(2):311-21. PubMed ID: 19609669
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Down-regulation of phosphatidylinositol 3'-kinase/AKT/molecular target of rapamycin metabolic pathway by primary letrozole-based therapy in human breast cancer.
    Generali D; Fox SB; Brizzi MP; Allevi G; Bonardi S; Aguggini S; Milani M; Bersiga A; Campo L; Dionisio R; Vergoni F; Giardini R; Dogliotti L; Bottini A; Harris AL; Berruti A
    Clin Cancer Res; 2008 May; 14(9):2673-80. PubMed ID: 18451231
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Macrophage migration inhibitory factor (MIF) promotes cell survival by activation of the Akt pathway and role for CSN5/JAB1 in the control of autocrine MIF activity.
    Lue H; Thiele M; Franz J; Dahl E; Speckgens S; Leng L; Fingerle-Rowson G; Bucala R; Lüscher B; Bernhagen J
    Oncogene; 2007 Aug; 26(35):5046-59. PubMed ID: 17310986
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Curcumin down-regulates the multidrug-resistance mdr1b gene by inhibiting the PI3K/Akt/NF kappa B pathway.
    Choi BH; Kim CG; Lim Y; Shin SY; Lee YH
    Cancer Lett; 2008 Jan; 259(1):111-8. PubMed ID: 18006147
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Determination of the optimal combination chemotherapy regimen for treatment of platinum-resistant ovarian cancer in nude mouse model.
    Saucier JM; Yu J; Gaikwad A; Coleman RL; Wolf JK; Smith JA
    J Oncol Pharm Pract; 2007 Mar; 13(1):39-45. PubMed ID: 17621566
    [TBL] [Abstract][Full Text] [Related]  

  • 12. In vivo antitumor activity of MEK and phosphatidylinositol 3-kinase inhibitors in basal-like breast cancer models.
    Hoeflich KP; O'Brien C; Boyd Z; Cavet G; Guerrero S; Jung K; Januario T; Savage H; Punnoose E; Truong T; Zhou W; Berry L; Murray L; Amler L; Belvin M; Friedman LS; Lackner MR
    Clin Cancer Res; 2009 Jul; 15(14):4649-64. PubMed ID: 19567590
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Intermittent administration of MEK inhibitor GDC-0973 plus PI3K inhibitor GDC-0941 triggers robust apoptosis and tumor growth inhibition.
    Hoeflich KP; Merchant M; Orr C; Chan J; Den Otter D; Berry L; Kasman I; Koeppen H; Rice K; Yang NY; Engst S; Johnston S; Friedman LS; Belvin M
    Cancer Res; 2012 Jan; 72(1):210-9. PubMed ID: 22084396
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Activation of the PI3K/AKT pathway mediates FSH-stimulated VEGF expression in ovarian serous cystadenocarcinoma.
    Huang Y; Hua K; Zhou X; Jin H; Chen X; Lu X; Yu Y; Zha X; Feng Y
    Cell Res; 2008 Jul; 18(7):780-91. PubMed ID: 18574502
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Up-regulation of PI3K/Akt signaling by 17beta-estradiol through activation of estrogen receptor-alpha, but not estrogen receptor-beta, and stimulates cell growth in breast cancer cells.
    Lee YR; Park J; Yu HN; Kim JS; Youn HJ; Jung SH
    Biochem Biophys Res Commun; 2005 Nov; 336(4):1221-6. PubMed ID: 16169518
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Aberration of the PI3K/AKT/mTOR signaling in epithelial ovarian cancer and its implication in cisplatin-based chemotherapy.
    Zhang HY; Zhang PN; Sun H
    Eur J Obstet Gynecol Reprod Biol; 2009 Sep; 146(1):81-6. PubMed ID: 19540648
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Pharmacokinetic-pharmacodynamic modeling of tumor growth inhibition and biomarker modulation by the novel phosphatidylinositol 3-kinase inhibitor GDC-0941.
    Salphati L; Wong H; Belvin M; Bradford D; Edgar KA; Prior WW; Sampath D; Wallin JJ
    Drug Metab Dispos; 2010 Sep; 38(9):1436-42. PubMed ID: 20538720
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The phosphatidyl inositol 3-kinase/AKT signaling pathway in breast cancer.
    Castaneda CA; Cortes-Funes H; Gomez HL; Ciruelos EM
    Cancer Metastasis Rev; 2010 Dec; 29(4):751-9. PubMed ID: 20922461
    [TBL] [Abstract][Full Text] [Related]  

  • 19. More antitumor efficacy of the PI3K inhibitor GDC-0941 in breast cancer with PIK3CA mutation or HER2 amplification status in vitro.
    Zheng J; Wang H; Yao J; Zou X
    Pharmazie; 2014 Jan; 69(1):38-42. PubMed ID: 24601221
    [TBL] [Abstract][Full Text] [Related]  

  • 20. PIKing the right patient.
    Turke AB; Engelman JA
    Clin Cancer Res; 2010 Jul; 16(14):3523-5. PubMed ID: 20538763
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.